Anna Iolanda Rispoli

Department of Oncology, Medical Oncology Unit, San Giovanni di Dio and Ruggi d'Aragona, via San Leonardo, Salerno, Italy

Publications

• Research Article   
  Ribociclib/Letrozole Combination for the Treatment of Locally Advanced Hr+/Her2-Breast Cancer: A Real-World Experience
  Author(s): Anna Iolanda Rispoli, Chiara de Divitiis, Celeste Fusciello, Fortuna Lombardi and Clementina Savastano*
  
  Locally Advanced Breast Cancer (LABC) is a heterogenous disease not amenable for primary surgery. Neoadjuvant therapy has been shown to improve outcomes in patients with inoperable de novo Hormone Receptor-positive/Human Epidermal Growth factor receptor 2-negative (HR+/HER2-) locally advanced breast cancer. An Italian retrospective single-center study included 23 de novo HR+/HER2-LABC patients, treated with first-line ribociclib plus letrozole. The clinical response was analyzed both at biological and clinical level. At baseline, 15 (65.2%) women had stage IIIA ductal carcinoma; median Ki-67 expression was 15% (range: 10-80%) and 13 patients (56,5%) had Ki-67 under 20%. After treatment, 68.5% of patients achieved overall response with 1 clinical complete response; 73.9% were eligible for surgery. Following surgery, 88% experienced TNM downstaging and .. Read More»